These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26766738)

  • 21. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    Aranda E; García-Alfonso P; Benavides M; Sánchez Ruiz A; Guillén-Ponce C; Safont MJ; Alcaide J; Gómez A; López R; Manzano JL; Méndez Ureña M; Sastre J; Rivera F; Grávalos C; García T; Martín-Valadés JI; Falcó E; Navalón M; González Flores E; Ma García Tapiador A; Ma López Muñoz A; Barrajón E; Reboredo M; García Teijido P; Viudez A; Cárdenas N; Díaz-Rubio E;
    Eur J Cancer; 2018 Sep; 101():263-272. PubMed ID: 30054049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
    Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
    Nishina T; Takano Y; Denda T; Yasui H; Takeda K; Ura T; Esaki T; Okuyama Y; Kondo K; Takahashi Y; Sugiyama Y; Muro K
    Jpn J Clin Oncol; 2013 Nov; 43(11):1080-6. PubMed ID: 23999770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
    Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
    Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
    Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
    Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
    Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
    Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
    Assenat E; Desseigne F; Thezenas S; Viret F; Mineur L; Kramar A; Samalin E; Portales F; Bibeau F; Crapez-Lopez E; Bleuse JP; Ychou M
    Oncologist; 2011; 16(11):1557-64. PubMed ID: 22016477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
    Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
    Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
    García-Carbonero R; van Cutsem E; Rivera F; Jassem J; Gore I; Tebbutt N; Braiteh F; Argiles G; Wainberg ZA; Funke R; Anderson M; McCall B; Stroh M; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Hurwitz H
    Oncologist; 2017 Apr; 22(4):375-e30. PubMed ID: 28275117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
    Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.